Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

• US 9,657,102 B2
• Filed: 09/19/2013
• Issued: 05/23/2017
• Est. Priority Date: 09/21/2012
• Status: Active Grant

• Current Assignee: Regeneron Pharmaceuticals Incorporated
• Original Assignee: Regeneron Pharmaceuticals Incorporated
• Inventors: Smith, Eric, Papadopoulos, Nicholas J.
• Primary Examiner(s): Juedes, Amy
• Application Number:
  US14/031,075
• Publication Number:
  US 20140088295A1
• Time in Patent Office: 1,342 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/35 Valency
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

Claims

1. A fully human bispecific antibody comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) contained within any one heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:

1250, 1266, 1282, 1298, and 1314, the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) contained within the HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and the first antigen-binding domain and the second antigen-binding domain each comprise three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within any one light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs;

1258, 1274, 1290, 1306, and 1322.

2. The fully human bispecific antibody of claim 1, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3), comprising the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs:

1252-1254-1256, 1268-1270-1272, 1284-1286-1288, 1300-1302-1304, and 1316-1318-1320, and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), comprising the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs;

1260-1262-1264, 1276-1278-1280, 1292-1294-1296, 1308-1310-1312, and 1324-1326-1328.

3. The fully human bispecific antibody of claim 2, wherein the first antigen-binding domain that specifically binds human CD3 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:

1250, 1266, 1282, 1298, and 1314, and a light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs;

1258, 1274, 1290, 1306, and 1322.

4. The fully human bispecific antibody of claim 1, wherein the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3), and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3),wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:

1244, A2-HCDR2comprises the amino acid sequence of SEQ ID NO;

1246, and A2-HCDR3 comprises the amino acid sequence of SEQ ID NO;

1248, and wherein A2-LCDR1, A2-LCDR2, and A3-LCDR3,comprise the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs;

1260-1262-1264, 1276-1278-1280, 1292-1294-1296, 1308-1310-1312, and 1324-1326-1328.

5. The fully human bispecific antibody of claim 4,

wherein the first antigen-binding domain that specifically binds human CD3comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2and A1-HCDR3), comprising the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs:

1252-1254-1256, 1268-1270-1272, 1284-1286-1288, 1300-1302-1304,and 1316-1318-1320, and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), comprising the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs;

1260-1262-1264, 1276-1278-1280, 1292-1294-1296, 1308-1310-1312, and 1324-1326-1328; and

wherein the second antigen-binding domain that specifically binds human CD20comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2and A2-HCDR3), comprising the amino acid sequences, respectively, of SEQ ID NOs;

1244-1246-1248, and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2and A2-LCDR3), comprising the amino acid sequences, respectively, selected from the group consisting of SEQ ID NOs;

1260-1262-1264, 1276-1278-1280, 1292-1294-1296, 1308-1310-1312, and 1324-1326-1328.

6. The fully human bispecific antibody of claim 4, wherein the second antigen-binding domain that specifically binds human CD20 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:

1242, and a light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs;

1258, 1274, 1290, 1306, and 1322.

7. The fully human bispecific antibody of claim 6, wherein the first antigen-binding domain that specifically binds human CD3 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs:

1250, 1266, 1282, 1298, and 1314, and a light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs;

1258, 1274, 1290, 1306, and 1322; and

wherein the second antigen-binding domain that specifically binds human CD20 comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO;

1242, and a light chain variable region (LCVR) comprising the amino acid sequence selected from the group consisting of SEQ ID NOs;

1258, 1274, 1290, 1306, and 1322.

8. The fully human bispecific antibody of claim 7, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:

1266, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1274, and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1274.

9. The fully human bispecific antibody of claim 7, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:

1282, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1290, and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1290.

10. The fully human bispecific antibody of claim 7, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:

1298, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1306, and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1306.

11. The fully human bispecific antibody of claim 7, wherein the first antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO:

1314, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1322, and wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1322.

12. A fully human bispecific antibody comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20;

wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO;

1250, and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO;

1258; and

wherein the second antigen-binding domain comprises a HCVR comprising the amino acid sequence of SEQ ID NO;

1242, and a LCVR comprising the amino acid sequence of SEQ ID NO;

1258.